天津医药 ›› 2016, Vol. 44 ›› Issue (9): 1181-1184.doi: 10.11958/20160019

• 综述 • 上一篇    

混合型肝癌的最新研究进展

刘东明, 陈璐, 田垚, 张希昊, 李强   

  1. 天津医科大学肿瘤医院, 国家肿瘤临床医学研究中心, 天津市“肿瘤防治”重点实验室(邮编 300060)
  • 收稿日期:2016-01-15 修回日期:2016-05-22 出版日期:2016-09-15 发布日期:2016-09-28
  • 通讯作者: 李强 E-mail:liqiang4016@yahoo.com
  • 作者简介:刘东明(1991), 男, 硕士在读, 主要从事肝胆肿瘤方面研究

Current update on combined hepatocellular and cholangiocarcinoma

LIU Dongming, CHEN Lu, TIAN Yao, ZHANG Xihao, LI Qiang△   

  1. Tianjin Medical University Cancer Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
  • Received:2016-01-15 Revised:2016-05-22 Published:2016-09-15 Online:2016-09-28
  • Contact: LI Qiang E-mail:liqiang4016@yahoo.com

摘要: 混合型肝癌是一类兼具肝细胞肝癌和胆管细胞癌分化特点的原发性肝肿瘤。 其发病原因可能与乙型、丙型肝炎病毒感染有关。 混合型肝癌的治疗方式以手术治疗为主, 同时辅以射频消融(RFA)、经导管动脉内化疗栓塞术(TACE)及综合治疗。 在临床工作中, 由于混合型肝癌的发病率较低, 且其症状、体征不典型, 常与另外 2 种原发性肝癌发生混淆。 因此, 对于混合型肝癌最新进展的了解就显得尤为重要, 本文就目前混合型肝癌的流行病学和临床特点、治疗方式和预后及基因分子生物学前沿等方面的研究进行综述。

关键词: 癌, 肝细胞, 胆管肿瘤, 综述, 混合型肝癌

Abstract: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary hepatic neoplasm (PHN) with features of both hepatocellular and biliary differentiation. Hepatitis B and hepatitis C are the major causes of HCC-CC. Surgical treatment is the main therapeutic method for HCC-CC. For patients with unresectable lesions, curative or palliative locoregional therapy is applied, including radiofrequency ablation (RFA), transarterial chemoembolization (TACE) and supportive treatment. Because of the rare occurrence and ambiguous clinical features of HCC- CC, it is most often misdiagnosed with the other two types of primary liver cancer. Thus, the realization of the current progress of combined hepatocellular and cholangiocarcinoma is particularly important for us. This article aims to summarize the epidemiology and clinical futures, the treatment and prognosis, the progress of genetics and molecular analysis of HCC-CC.

Key words: carcinoma, hepatocellular, bile duct neoplasms, review, combined hepatocellular and cholangiocarcinoma